{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-018553","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.047286+00:00","generated_at":"2026-06-18T08:21:41.721029+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"OptimizeRx Q4 revenue $19.7M (-3% YoY); guides FY23 revenue growth at least 10%","bullets":["Q4 revenue $19.7M (-3% YoY), gross profit $12.5M (+1%), GAAP net loss $0.3M ($0.02 loss per share).","Non-GAAP net income $4.4M ($0.25 per diluted share).","FY22 revenue up 2%, generated $10.7M cash from ops, repurchased 1.2M shares at avg $16.49.","Exited 2022 with six RWD-AI deals; pipeline of several dozen.","FY23 guidance: revenue growth at least 10% YoY, gross margin 58-62%; Q1 revenue $11.5-13M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-018553","json":"https://secwatch.observer/filing/0001213900-23-018553.json","markdown":"https://secwatch.observer/filing/0001213900-23-018553.md","text":"https://secwatch.observer/filing/0001213900-23-018553.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390023018553/0001213900-23-018553-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390023018553/ea174846-8k_optimizerx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:21:41.721029+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f61613beff04d8ce7e89782010e99a02ed67c338","claim":"OptimizeRx Corp reported the fourth quarter and year ended December 31, 2022 results: revenue $19.7 million, net income GAAP net loss totaled $(0.3) million or $(0.02) per basic and diluted share, EPS $(0.02) per basic and diluted share. Guidance initiated.","evidence_excerpt":"2 ea174846ex99-1_optimizerx.htm PRESS RELEASE, DATED MARCH 8, 2023 Exhibit 99.1 OptimizeRx Reports Fourth Quarter and Full Year 2022 Financial Results - Q4 revenue of $19.7 million, down 3% year-over-year and up 30% quarter-over-quarter - Q4 gross profit increased 1% year-over-year to $12.5 million as gross margins increased from 61% to 63% -","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390023018553/0001213900-23-018553-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Revenue","value":"$19.7 million"},{"label":"Net income","value":"GAAP net loss totaled $(0.3) million or $(0.02) per basic and diluted share"},{"label":"EPS","value":"$(0.02) per basic and diluted share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}